乌罗立素改善了帕金森病的罗农模型中的α-synuclein聚合和DNMT1表达
Ankita Devi1, Sharon Munagalasetty2, Pardeep Kumar3
1Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana, India.
Neurotoxicology
|April 25, 2025
概括
乌罗利在打击阿尔法-同核素聚合方面表现出潜力,这是帕金森病和相关疾病的关键因素. 乌罗立A和其他衍生品在体和体外与聚合相关蛋白质显著相互作用.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔法-同核素聚合是神经退行性疾病的中心病理标志,如帕金森病 (PD),勒维体痴呆 (DLB) 和多个系统缩 (MSA).
- 了解分子机制并确定抑制α-synuclein聚合的治疗点,对于开发有效的治疗方法至关重要.
研究的目的:
- 调查各种urolithins (UA,UB,UC,UD,UE,UM5,UM6) 针对α-synuclein聚合的多重准潜力.
- 用计算和实验方法阐明urolithins与参与α-synuclein聚合,levodopa代谢和线粒体功能障碍的关键蛋白的相互作用.
主要方法:
- 在分析包括蛋白质-蛋白质对接和连接器对接研究,针对诸如α-synuclein (1XQ8),catechol-o-methyltransferase (1H1D),monoamine oxidase-B (2BK3),NADH脱酶 (3IAM),Sirtuin-1 (4I5I) 和DNA甲基转移酶-1 (5WVO) 等蛋白质.
- 进行了分子动力学模拟,以评估urolithin-蛋白质复合物的稳定性.
- 使用Neuro 2A细胞进行体外研究,以评估urolithin-A对DNMT1和α-synuclein表达的作用.
主要成果:
- 乙胆酶 (AChE,5HF9) 被确定为α-synuclein聚合中的潜在核子.
- 乌罗立A (UA) 与α-synuclein单体 (1XQ8),Sirtuin-1 (4I5I) 和DNA甲基转移酶-1 (5WVO) 形成稳定的复合体.
- 其他urolithins (UE,UM5,UC,UD) 与AChE (5HF9),单胺氧化酶-B (2BK3),甲基转移酶 (1H1D) 和NADH脱酶 (3IAM) 呈现稳定的相互作用.
- 乌罗立-A证明了有利的血脑屏障透性,并逆转了DNMT1抑制剂和Neuro 2A细胞中Rotenone诱导的DNMT1和α-synuclein表达的下降.
结论:
- 乌罗利,特别是UA,UC,UD,UE和UM5,作为针对α-synuclein聚合的多重向剂具有显著的潜力.
- 这些发现表明,urolithins是以α-synuclein病理为特征的神经退行性疾病的有前途的治疗候选者.
关键词:
在 DNMT1 中,DNMT1 的值是:分子对接是分子对接.分子动力学模拟模型蛋白质与蛋白质的对接乌罗利素是一种乌罗利素.α-synucleinopathies,即α-synucleinopathies,即α-synucleinopathies,即α-synucleinopathies,即α-synucleinopathies,即α-synucleinopathies,即α-synucleinopathies,即α-synucleinopathies,即α-synucleinopathies,即α-synucleinopathies,即α-synucleinopathies,即α-synucleinopathies,即α-synucleinopathies,即α-synucleinopathies,即α-synucleinopathies,即α-synucleinopathies,即α-synucleinopathies,即α-synucleinopathies,即α-synucleinopathies,即α-synucleinopathies,即α-synucleinopathies,即α-synucleinopathies,即α-synucleinopathies.
相关概念视频
01:24Parkinson's Disease: Treatment
148
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
148
01:37Neural Regulation
39.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.0K
01:15Parkinson's Disease: Overview
310
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
310
01:22Lysosomal Hydrolases
3.7K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.7K